"Attikon" University Hospital
Welcome,         Profile    Billing    Logout  
 3 Trials 
9 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Koumarianou, Anna
ALTA-3, NCT03596866 / 2018-001957-29: A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

Checkmark Brigatinib vs Alectinib in Crizotinib-Resistant Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALTA-3).
Checkmark Phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
Recruiting
3
246
Europe, Canada, US, RoW
Brigatinib, Alunbrig, Alectinib, Alecensa
Takeda
ALK+ Advanced NSCLC
09/21
05/24
RETRO-TAS, NCT04965870: A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece

Recruiting
N/A
200
Europe
Trifluridine/Tipiracil, FTD/TPI, TAS 102
Hellenic Study Group of Psychoneuroimmunology in Cancer, Servier
Metastatic Colorectal Cancer
10/21
12/21
Psyrri, Amanda
eMonarcHER, NCT04752332 / 2020-004035-24: A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

Checkmark [VIRTUAL] eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.
Recruiting
3
2450
Europe, Japan, US, RoW
Abemaciclib, LY2835219, Standard Adjuvant ET, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms
05/25
02/33
NCT01969578 / 2013-000314-38: Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

Checkmark Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) inpatients with recurrent and/or metastatic androgen receptor (AR) express…
Checkmark Phase II trial of abiraterone acetate in patients with relapsed and/or metastatic, castration resistant AR expressing salivary glands carcinomas (SGCs)
Checkmark Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expres…
Recruiting
2
152
Europe
bicalutamide + triptorelin, Cisplatin + Doxorubicin, Carboplatin + Paclitaxel
European Organisation for Research and Treatment of Cancer - EORTC, European Organisation for Research and Treatment of Cancer (EORTC), Bluefish Pharmaceuticals AB, Debiopharm Research & Manufacturing, Fonds Baillet Latour, AIRC, & Fondazione IRCCS Istituto Nazionale dei Tumori, RARECAREnet, Cancer Research UK, Fondazione IRCCS Istituto Nazionale dei Tumori, Debiopharm Research and Manufacturing, European Organisation for Research and Treatment o, Fondazione IRCCS IstitutoNazionale dei Tumori di M
Salivary Gland Cancer
06/22
06/22
CERPASS, NCT04050436: Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

Checkmark [VIRTUAL] A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]
Recruiting
2
180
Europe, Canada, US, RoW
Cemiplimab, Libtayo, RP1, Genetically modified herpes simplex type 1 virus
Replimune Inc., Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
10/22
03/25
NCT04632173: Head and Neck cancERs International cOviD-19 collabOraTion

Checkmark [VIRTUAL] HERODOTUS: Head and neck cancers international COVID-19 collaboration: An international registry on head and neck cancer with COVID-19
Recruiting
N/A
750
Europe, RoW
non interventional study
Hellenic Cooperative Oncology Group, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Grupo Español de Tratamiento de Tumores de Cabeza y Cuello, National Cancer Centre, Singapore, Emory University, University of Toronto, University of Birmingham, The University of Queensland
Head and Neck Cancer, Covid19
12/21
06/22
NCT03652142: Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma

Checkmark Predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma (HNSCC) (NCT#03652142).
Recruiting
N/A
50
Europe
Biomarker Research, Nivolumab, Opdivo
Attikon Hospital
HNSCC, DNA Damage, DNA Double Strand Break
05/20
05/20
NCT04490564: A Clinical Performance Study to Validate the Use of Novel Molecular Diagnostic Assays for the Detection of Cancer Biomarkers in Peripheral Blood and Primary Tumor Tissue of Patients With Recurrent/Metastatic HNSCC, Metastatic NSCLC or Metastatic Melanoma

Recruiting
N/A
185
Europe
PD-L1 Kit
Pharmassist Ltd, University of Athens
Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma
12/20
12/21
NCT04480814: A Clinical Performance Study to Validate the Use of Novel Molecular Diagnostic Assays for the Detection of Cancer Biomarkers in Peripheral Blood and Primary Tumor Tissue Samples of Patients With Metastatic ER+/HER2- Breast Cancer

Recruiting
N/A
120
Europe
PIK3CA kit
Pharmassist Ltd, University of Athens
Breast Cancer
04/21
10/21

Download Options